DSKYF
Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 32.17$. Average daily volumn in 3 months 13.04k. Market cap 66.13B
Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD Lastest price : 34.50$. Total volume : 26.00. Market state REGULAR Click reload if you want to check the lastest price on market!!!
Daiichi Sankyo Company, Limited (DSKYF)
Last Price
34.50$Change
0.00Volume
26.00
| Previous Close | 34.50 |
| Open | 34.50 |
| Day Range | 34.50-34.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Volume | 26 |
| Average Volume | 13.04k |
| Market Cap | 66.13B |
| Beta | 0.48 |
| 52 Week Range | 19.76-34.50 |
| Trailing P/E | 150.00 |
| Foward P/E | 51.49 |
| Dividend (Yield %) | 0.68% |
| Ex-Dividend Date | 2023-03-30 |
Financial Details
Organization
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; and ferric carboxymaltose injection for treating anemia. It also provides edoxaban, an oral, once-daily, direct factor Xa inhibitor; esaxerenone and olmesartan medo... xomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgality for the treatment of migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastases from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Market Cap:
66.13BRevenue:
1.04TTotal Assets:
2.22TTotal Cash:
662.48B
News about "Daiichi Sankyo Company, Limited"
Daiichi Sankyo Company, Limited (4568.T)
Source from : Yahoo Finance - 1 days ago
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...See details»
Daiichi Sankyo Co Ltd
Source from : Reuters - 14 days ago
Healthcare & Pharmaceuticalscategory Gilead's breast cancer drug gets U.S. FDA approval for third indication, article with image February 3, 2023 Businesscategory Japan's Daiichi Sankyo applies ...See details»
Daiichi Sankyo Company, Limited (DSKYF)
Source from : Yahoo Finance - 5 month ago
TOKYO & BASKING RIDGE, N.J., February 17, 2023--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its ...See details»
Could Daiichi Sankyo have another ADC winner in cancer?
Source from : pharmaphorum - 1 days ago
Daiichi Sankyoโs antibody-drug conjugate (ADC) platform has already delivered one drug to the market with blockbuster sales forecasts, with a second due to be filed shortly. Now, a third is showing ...See details»
Daiichi Sankyo claims first okay for oncolytic virus in Japan
Source from : pharmaphorum - 1 month ago
Daiichi Sankyo has made a little bit of pharma industry ... has granted a conditional approval to the company's Delytact (teserpaturev) for the treatment of patients with malignant glioma, an ...See details»
Esperion extends selloff as Daiichi Sankyo dispute prompts BofA downgrade
Source from : Seeking Alpha on MSN - 5 days ago
Esperion Therapeutics (ESPR) continued the post-market selloff on Thursday as Bank of America downgraded it due to a payment dispute with Daiichi Sankyo (DSNKY). Read the full story here.See details»
Daiichi Sankyo applies for approval of mRNA COVID vaccine
Source from : ๆๆฅๆฐ่็คพ - 6 days ago
the company said in November. Daiichi Sankyo said it plans to move forward to develop DS-5670 to target the Omicron strain of the coronavirus.See details»
Daiichi Sankyo Co Stock (OTC:DSNKY), Analyst Ratings, Price Targets, Predictions
Source from : Benzinga.com - 9 month ago
Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...See details»
Daiichi Sankyo Co. Ltd. ADR
Source from : Wall Street Journal - 1 month ago
1 Day DSNKY 1.64% DJIA 0.39% S&P 500 -0.28% Health Care/Life Sciences 0.71% Sunao Manabe President, CEO & Representative Director Daiichi Sankyo Co., Ltd. Hiroyuki Okuzawa CFO, Director & General ...See details»
Daiichi Sankyo Company, Limited (DSKYF)
Source from : Yahoo Finance - 1 month ago
TOKYO & BASKING RIDGE, N.J., February 17, 2023--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request ...See details»
Daiichi Sankyo Co., Ltd.
Source from : Nikkei Asia - 27 days ago
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan ...See details»
Daiichi Sankyo Company, Limited (DSKYF)
Source from : Yahoo Finance - 1 month ago
TOKYO & BASKING RIDGE, N.J., February 17, 2023--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request ...See details»
Daiichi Sankyo Co., Ltd.
Source from : Nikkei Asia - 1 month ago
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan ...See details»
Daiichi Sankyo Company, Limited (DSKYF)
Source from : Yahoo Finance - 1 year ago
TOKYO & BASKING RIDGE, N.J., February 17, 2023--Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request ...See details»